Thomas Malley is Director at Kiniksa Pharmaceuticals, Ltd. (KNSA). They have made 11 open-market trades across 7 companies since 2007, most recently 2026-05-29.
CIK 0001403322
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
10 open-market purchases totalling $5.1M since 2007, against 1 sale. Across 8 scored buys the stock is down 7.0% at ninety days, and 8.6 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 0% | 13% |
| Avg Move | -27.0% | -6.9% | -7.0% |
| Alpha | -23.2% | -7.1% | -8.6% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KNSA | SELL | 2025-08-12 | 2025-08-14 | $32.96 | $11.7M | +1.4% | +10.5% | +22.6% |
| KURA | BUY | 2023-06-16 | 2023-06-21 | $11.50 | $575K | -3.9% | -0.2% | -12.7% |
| BGNE | BUY | 2016-11-23 | 2016-11-28 | $32.00 | $960K | -13.3% | -4.3% | +22.5% |
| KURA | BUY | 2015-11-10 | 2015-12-17 | $8.00 | $400K | -20.9% | -34.7% | -49.7% |
| OVAS | BUY | 2015-04-08 | 2015-04-09 | $28.50 | $143K | -32.7% | -2.1% | -2.1% |
| OVAS | BUY | 2015-01-13 | 2015-01-15 | $50.00 | $1.8M | -32.7% | -2.1% | -2.1% |
| OVSC | BUY | 2013-03-18 | 2013-03-20 | $9.00 | $450K | N/A | N/A | N/A |
| PBYI | BUY | 2012-10-24 | 2012-10-25 | $16.00 | $160K | -37.6% | -4.0% | -4.0% |
| PBYI | BUY | 2012-06-11 | 2012-06-13 | $12.50 | $125K | -37.6% | -4.0% | -4.0% |
| PBYI | BUY | 2012-06-07 | 2012-06-11 | $12.50 | $125K | -37.6% | -4.0% | -4.0% |
| CGRB | BUY | 2007-07-17 | 2007-07-20 | $21.75 | $433K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| 35,763 |
| — |
| OVSC | 81,819 | — |
| CGRB | 19,918 | — |
| Total | $13.6M |
Shares reported on the most recent Form 4, priced at the 2026-06-02 close. 4 holdings could not be priced and are excluded from the total.